Targeted inactivation of EWSR1::FLI1 gene in Ewing sarcoma via CRISPR/Cas9 driven by an Ewing-specific GGAA promoter
We have recently demonstrated that genetic inactivation of EWSR1::FLI1 by CRISPR/Cas9, successfully blocks cell proliferation in a cell model of Ewing sarcoma.
We have recently demonstrated that genetic inactivation of EWSR1::FLI1 by CRISPR/Cas9, successfully blocks cell proliferation in a cell model of Ewing sarcoma.
The study shows that a CRISPR/Cas9 system driven by a tumor‑specific GGAA promoter can selectively inactivate the EWSR1::FLI1 oncogenic fusion and halt the growth of Ewing sarcoma cells, offering a potential gene‑editing therapeutic approach for this aggressive cancer.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Revisiting CDKN2A dysregulation in Ewing sarcoma
- Emerging therapies in Ewing sarcoma
- Genome‑wide association study meta‑analysis identifies susceptibility loci informing Ewing sarcoma etiology and potential mechanisms of risk
- Biochemists discover new strategy to combat pediatric bone cancer
- Integrated Immunotherapy Target Atlas for Ewing Sarcoma